Esperion Therapeutics, Inc. (ESPR) Reaches $73.26 After 4.00% Up Move; Conmed (CNMD) SI Increased By 4.68%

January 14, 2018 - By Migdalia James

The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) is a huge mover today! The stock increased 4.79% or $3.35 during the last trading session, reaching $73.26. About 917,587 shares traded or 68.34% up from the average. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since January 14, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.The move comes after 7 months positive chart setup for the $1.92B company. It was reported on Jan, 14 by Barchart.com. We have $76.19 PT which if reached, will make NASDAQ:ESPR worth $76.76M more.

Conmed Corporation (NASDAQ:CNMD) had an increase of 4.68% in short interest. CNMD’s SI was 981,000 shares in January as released by FINRA. Its up 4.68% from 937,100 shares previously. With 100,300 avg volume, 10 days are for Conmed Corporation (NASDAQ:CNMD)’s short sellers to cover CNMD’s short positions. The SI to Conmed Corporation’s float is 4%. The stock increased 0.57% or $0.32 during the last trading session, reaching $56.48. About 138,631 shares traded or 23.01% up from the average. CONMED Corporation (NASDAQ:CNMD) has risen 27.59% since January 14, 2017 and is uptrending. It has outperformed by 10.89% the S&P500.

CONMED Corporation, a medical technology company, develops, makes, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has market cap of $1.58 billion. The firm offers sports medicine products, such as powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bio absorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; and sports biologics and tissues. It has a 102.88 P/E ratio. It also provides electrosurgical generators, hand pieces, smoke management systems, and accessories for surgical needs; and endomechanical instrumentation products that offer various instruments comprising trocars, suction irrigation devices, graspers, scissors, and dissectors used in the minimally invasive laparoscopic and gynecological surgery, as well as an uterine manipulator for use in the laparoscopic hysterectomies and other gynecologic laparoscopic procedures.

Among 6 analysts covering CONMED Corporation (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. CONMED Corporation had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by Needham on Thursday, July 27 with “Buy”. The firm has “Neutral” rating given on Thursday, August 27 by Piper Jaffray. The rating was upgraded by Ladenburg Thalmann to “Buy” on Monday, October 12. As per Wednesday, July 22, the company rating was downgraded by Northland Capital. The stock has “Hold” rating by KeyBanc Capital Markets on Wednesday, August 23. Needham maintained CONMED Corporation (NASDAQ:CNMD) rating on Tuesday, October 10. Needham has “Buy” rating and $57.0 target. Northland Capital maintained the stock with “Market Perform” rating in Thursday, October 22 report. The rating was maintained by KeyBanc Capital Markets with “Hold” on Friday, November 3. The firm earned “Buy” rating on Thursday, August 31 by Needham. The company was maintained on Friday, November 17 by Needham.

Investors sentiment increased to 1.34 in Q3 2017. Its up 0.07, from 1.27 in 2017Q2. It improved, as 16 investors sold CONMED Corporation shares while 34 reduced holdings. 16 funds opened positions while 51 raised stakes. 27.14 million shares or 1.19% more from 26.82 million shares in 2017Q2 were reported. Pacad Limited stated it has 1,000 shares. Quantbot Technology L P reported 2,543 shares or 0.01% of all its holdings. Washington-based Parametric Assoc Limited Liability Corporation has invested 0% in CONMED Corporation (NASDAQ:CNMD). Washington-based Fisher Asset Management Ltd Co has invested 0.05% in CONMED Corporation (NASDAQ:CNMD). New York State Teachers Retirement System holds 62,091 shares. 10,100 are owned by Louisiana State Employees Retirement System. Employees Retirement System Of Ohio accumulated 0% or 1,921 shares. Geode Cap Management Llc has invested 0% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Champlain Inv Partners Ltd Company accumulated 1.66 million shares. Blackrock holds 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 3.20 million shares. Us Bank & Trust De owns 571 shares. Cna Fincl Corp has 0.07% invested in CONMED Corporation (NASDAQ:CNMD). Strs Ohio holds 0% or 19,200 shares. Nationwide Fund Advsr accumulated 72,085 shares. Victory Cap Mgmt owns 2.18 million shares for 0.26% of their portfolio.

Since August 14, 2017, it had 1 buying transaction, and 1 sale for $142,004 activity. On Monday, August 14 GOLDEN JO ANN sold $150,000 worth of CONMED Corporation (NASDAQ:CNMD) or 3,000 shares. $7,996 worth of CONMED Corporation (NASDAQ:CNMD) was bought by Farkas Charles on Wednesday, January 3.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. Esperion Therapeutics had 50 analyst reports since July 28, 2015 according to SRatingsIntel. Citigroup maintained the stock with “Buy” rating in Wednesday, June 29 report. Needham maintained it with “Strong Buy” rating and $58 target in Monday, March 20 report. Cowen & Co maintained the stock with “Buy” rating in Wednesday, October 18 report. On Wednesday, February 24 the stock rating was maintained by Barclays Capital with “Overweight”. Lake Street maintained the stock with “Buy” rating in Wednesday, June 29 report. The rating was upgraded by Needham on Monday, August 10 to “Buy”. The firm earned “Hold” rating on Friday, September 4 by Zacks. The company was upgraded on Tuesday, February 28 by Citigroup. The stock has “Underperform” rating by Credit Suisse on Wednesday, June 29. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Stifel Nicolaus on Thursday, February 25.

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Employees Retirement Systems Of Ohio holds 29,555 shares. 34,781 are owned by National Bank Of America De. Columbus Circle Investors reported 51,997 shares. Citadel Ltd Liability Corp holds 58,332 shares. 55,095 are owned by Guggenheim Limited Liability Corp. Moreover, Tiverton Asset Management Llc has 0.04% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Credit Suisse Ag invested in 0.05% or 1.06M shares. The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Comml Bank Of Montreal Can stated it has 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). United Kingdom-based Pictet Asset Mngmt Ltd has invested 0.04% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Tru Of Vermont has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Amundi Pioneer Asset invested 0.03% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Hall Laurie J Trustee accumulated 280 shares or 0.01% of the stock. Proshare Advisors Limited has 15,640 shares for 0.01% of their portfolio. Quantitative Invest Management Ltd Liability Com invested 0.07% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 earnings per share, down 39.53% or $0.51 from last year’s $-1.29 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23% EPS growth.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.92 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com